Other
Unrealized Gain (Loss) on Securities
Regeneron Pharmaceuticals Unrealized Gain (Loss) on Securities decreased by 1026.8% to -$65.80M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 272.7%, from $38.10M to -$65.80M. Over 2 years (FY 2021 to FY 2025), Unrealized Gain (Loss) on Securities shows an upward trend with a 21.3% CAGR.
Analysis
StatementIncome Statement
SectionOther
First reportedQ1 2013
Last reportedQ1 2026Apr 29, 2026
Metric ID:
cop_unrealized_gain_loss_on_securitiesHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$800.00K | -$6.40M | -$35.90M | -$144.90M | -$53.70M | -$51.30M | $57.20M | -$15.70M | $21.30M | $95.40M | $3.50M | $7.90M | $128.20M | $38.10M | $22.10M | $15.70M | $7.10M | -$65.80M |
| QoQ Change | — | -700.0% | -460.9% | -303.6% | +62.9% | +4.5% | +211.5% | -127.4% | +235.7% | +347.9% | -96.3% | +125.7% | >999% | -70.3% | -42.0% | -29.0% | -54.8% | <-999% |
| YoY Change | — | — | — | — | <-999% | -701.6% | +139.5% | +70.8% | +141.5% | — | -93.9% | +150.3% | +501.9% | +988.6% | +179.7% | -87.8% | — | -272.7% |
Range-$144.90M – $128.20M
CAGR+182.2%
Avg YoY Growth-466.3%
Median YoY Growth+105.1%
Current Streak5 quarters decline
Unrealized Gain (Loss) on Securities at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's unrealized gain (loss) on securities?
- Regeneron Pharmaceuticals (REGN) reported unrealized gain (loss) on securities of -$65.80M in Q1 2026.
- How has Regeneron Pharmaceuticals's unrealized gain (loss) on securities changed year-over-year?
- Regeneron Pharmaceuticals's unrealized gain (loss) on securities decreased by 272.7% year-over-year, from $38.10M to -$65.80M.
- What is the long-term trend for Regeneron Pharmaceuticals's unrealized gain (loss) on securities?
- Over 2 years (2021 to 2025), Regeneron Pharmaceuticals's unrealized gain (loss) on securities has grown at a 21.3% compound annual growth rate (CAGR), from -$56.40M to $83.00M.